MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, LLC, bioMérieux’s molecular biology affiliate, announced today that it has commenced clinical and analytical studies to evaluate the company’s ...

A multicenter evaluation of BioFire RP2.1 for the detection of SARS-CoV-2 in 524 nasopharyngeal swab samples was conducted by Berry et al. In this study, one or more targets on the panel were detected ...

Falsey AR, Branche AR, Croft DP, et al. Real-Life Assessment of BioFire FilmArray® Pneumonia Panel in Adults Hospitalized with Respiratory Illness. J Infect Dis. 2023 Jun 27:jiad221. doi: ...

Conventional routine PCR testing for gastrointestinal infections is generally based on pathogen related panels specifically requested by clinicians and can be erroneous and time consuming. The BioFire ...

June 7, 2013 -- BioFire Diagnostics Inc. announced today that it obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its FilmArray Blood Culture ...

Marcy l’Etoile, France – February 26, 2015 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, LLC, its molecular biology affiliate, received ...

Salt Lake City, UT – BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray system.